Evaluation of Ferric and Ferrous Iron Therapies in Women with Iron Deficiency Anaemia

Table 2

(a) A general analysis of 54 patients receiving Fe⁺³, 24 patients from the study, and the remaining 30 patients. (b) A general analysis of 50 patients receiving Fe⁺², 16 patients from the study, and the remaining 34 patients.

(a)

Parameters	Before treatment	After treatment	𝑃
Hg (g/dL)	11.2	12.4	S**
Htc (%)	34.2	36.8	S
RBC (×10^12/L)	4.3	4.6	S
MCV (fL)	79.8	82.4	S
MCH (pg/cell)	26.4	27.61	S
MCHC (g/dL)	33.3	33.3	NS*
Fe (𝜇g/dL)	18.3	68.2	S
TIBC (𝜇g/dL)	333	352.5	NS
Trans. sat. (%)	5.5	19.5	S
Ferritin (ng/dL)	9	12.3	S

∗NS: not statistically significant; ∗∗S: statistically significant.

(b)

Parameters	Before treatment	After treatment	𝑃
Hg (g/dL)	10.3	12.6	S
Htc (%)	32.07	37.9	S
RBC (×10^12/L)	4.37	4.70	S
MCV (fL)	72.5	82.1	S
MCH (pg/cell)	23	27	S
MCHC (g/dL)	31.5	33.2	S
Fe (𝜇g/dL)	22.7	61.9	S
TIBC (𝜇g/dL)	366.4	329.6	S
Trans. sat. (%)	6.2	18.52	S
Ferritin (ng/dL)	8.2	12.2	S